NLS Pharmaceutics (NASDAQ:NCEL) Shares Up 3.5% – What’s Next?

NLS Pharmaceutics Ltd. (NASDAQ:NCEL)’s stock price rose 3.5% during mid-day trading on Tuesday. The company traded as high as $3.20 and last traded at $2.96. Approximately 7,212 shares were traded during trading, an increase of 35% from the average daily volume of 5,342 shares. The stock had previously closed at $2.86.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Weiss Ratings upgraded NLS Pharmaceutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, September 18th. Laidlaw assumed coverage on NLS Pharmaceutics in a research note on Monday, July 13th. They issued a “buy” rating and a $23.00 price target for the company. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, NLS Pharmaceutics has an average rating of “Hold” and an average target price of $23.00.

NLS Pharmaceutics Price Performance

The business’s 50-day moving average price is $3.25 and its two-hundred day moving average price is $3.26.

NLS Pharmaceutics (NASDAQ:NCEL) last issued its quarterly earnings results on Friday, September 18th. The company reported ($0.48) earnings per share (EPS) for the quarter.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly sleep-related conditions. The company’s research is based on the role of orexin, a neurotransmitter involved in regulating wakefulness, arousal and energy balance.

NLS Pharmaceutics has developed a portfolio of small-molecule orexin receptor agonists, including AAZ-A-154 and AAZ-A-172. These investigational compounds are intended to address disorders associated with excessive daytime sleepiness and impaired wakefulness, including narcolepsy and other neurological conditions.